SURVEYOR-II: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 3 Infection

Press/Media: Press / Media

PeriodDec 2 2015

Media coverage

2

Media coverage

  • TitleSURVEYOR-II: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 3 Infection
    Media name/outletNational AIDS Treatment Advocacy Project
    CountryUnited States
    Date12/2/15
    PersonsFred Poordad
  • TitleSURVEYOR-II: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 2 Infection
    Media name/outletNational AIDS Treatment Advocacy Project
    CountryUnited States
    Date12/2/15
    PersonsFred Poordad